Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease

Genetics in Medicine

Volumn 10, Issue 10, 2008, Pages 758-762

  McDowell, Roddy ^a   Li, Jennifer S ^a,b   Benjamin Jr , Daniel Kelly ^a,b   Morgan, Claire ^c   Becker, Alison ^c   Kishnani, Priva S ^a   Kanter, Ronald J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

Arrhythmias; Cardiomyopathy; Enzyme replacement therapy; Glycogen storage disease type II; Pompe disease

Indexed keywords

DIGITOXIN; ENZYME; LIDOCAINE; MEXILETINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INFANT; MALE; METABOLIC STRESS; MULTICENTER STUDY; QT INTERVAL; RETROSPECTIVE STUDY; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL TIME;

ALPHA-GLUCOSIDASES; ARRHYTHMIAS, CARDIAC; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 56049108820     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318183722f     Document Type: Article

References (42)

1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;144:S35-S43.
2. Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase deficiency. New York: McGraw Hill, 2001.
3. Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-676.
4. Van den Hout HM, Hop W, Van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340.
5. Bharati S, Serratto M, DuBrow I, et al. The conduction system in Pompe's disease. Pediatr Cardiol 1982;2:25-32.
6. Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J 1978;96:246-252.
7. Francesconi M, Auff E, Ursin C, Sluga E. [WPW syndrome combined with AV block 2 in an adult with glycogenosis (Type II)] Wien Klin Wochenschr 1982;94:401-404.
8. Tabarki B, Mahdhaoui A, Yacoub M, et al. [Familial hypertrophic cardiomyopathy associated with Wolff-Parkinson-White syndrome revealing type II glycogenosis]. Arch Pediatr 2002;9:697-700.
9. Ansong AK, Li JS, Nozik-Grayck E, et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 2006;8:297-301.
10. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
11. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
12. Van den Hout IM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-274.
13. Van den Hout JM, Kamphoven IH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:448-457.
14. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31.
15. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97.
16. FDA approves first treatment for Pompe's disease, 2006. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01365.html. Accessed February 12, 2008.
17. European Medicines Agency: Committee for Medicinal Products for Human use, 2006. Available at: http://www.emea.europa.eu/pdfs/human/press/pr/ 3279606en.pdf. Accessed February 12, 2008.
18. Cook AL, Kishnani PS, Carboni MP, et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. Genet Med 2006;8:313-317.
19. Wang LY, Ross AK, Li JS, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth 2007;17:738-748.
20. Ing RJ, Cook DR, Bengur RA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 2004;14:514-519.
21. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993;72:23B-25B.
22. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993;87:1866-1872.
23. Vincent GM. Long QT syndrome. Cardiol Clin 2000;18:309-325.
24. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774-778.
25. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl I Med 2000;342:1778-1785.
26. Romeo F, Cianfrocca C, Pelliccia F, Colloridi V, Cristofani R, Reale R. Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis. Clin Cardiol 1990;13:101-107.
27. Grimm W, Christ M, Bach J, Muller HH. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003;108:2883-2891.
28. Azevedo VM, Santos MA, Albanesi Filho FM, Castier MB, Tura BR, Amino JG. Outcome factors of idiopathic dilated cardiomyopathy in children-a long-term follow-up review. Cardiol Young 2007;17:175-184.
29. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-372.
30. Arad M, Moskowitz IP, Patel W, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003;107:2850-2856.
31. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846.
32. Patel W, Arad M, Moskowitz IP, et al. Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Am Coll Cardiol 2003;42:942-951.
33. Sidhu JS, Rajawat YS, Rami TG, et al. Transgenic mouse model of ventricular pre-excitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 2005;111:21-29.
34. Moon J, Sheppard M, Reed E, Lee P, Elliott PM, Pannell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-482.
35. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-1518.
36. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000;35:36-44.
37. Yi G, Elliott P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1514-1519.
38. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992;15:739-742.
39. Sun ZH, Happonen JM, Bennhagen R, et al. Increased QT dispersion and loss of sinus rhythm as risk factors for late sudden death after Mustard or Senning procedures for transposition of the great arteries. Am J Cardiol 2004;94:138-141.
40. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-344.
41. Bonaduce D, Petretta M, Marciano F, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Am Heart J 1999;138:273-284.
42. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. J Am Coll Cardiol 1996;28:1183-1189.